{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:54:39Z","timestamp":1787698479516,"version":"build-2784847793"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"25","license":[{"start":{"date-parts":[[2017,2,6]],"date-time":"2017-02-06T00:00:00Z","timestamp":1486339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1038\/onc.2016.509","type":"journal-article","created":{"date-parts":[[2017,2,6]],"date-time":"2017-02-06T19:00:34Z","timestamp":1486407634000},"page":"3576-3587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["A loop of cancer-stroma-cancer interaction promotes peritoneal metastasis of ovarian cancer via TNF\u03b1-TGF\u03b1-EGFR"],"prefix":"10.1038","volume":"36","author":[{"given":"T-S","family":"Lau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L K-Y","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E C-H","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C W-C","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Sneddon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T-H","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S-F","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J H-S","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C S-Y","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T K-H","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,6]]},"reference":[{"key":"BFonc2016509_CR1","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel E . Ovarian cancer development and metastasis. Am J Pathol 2010; 177: 1053\u20131064.","journal-title":"Am J Pathol"},{"key":"BFonc2016509_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrc3432","volume":"13","author":"E Kipps","year":"2013","unstructured":"Kipps E, Tan DS, Kaye SB . Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer 2013; 13: 273\u2013282.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2016509_CR3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrc3144","volume":"11","author":"S Vaughan","year":"2011","unstructured":"Vaughan S, Coward JI, Bast Jr RC, Berchuck A, Berek JS, Brenton JD et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011; 11: 719\u2013725.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2016509_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0304-3835(95)03743-G","volume":"91","author":"MJ Gardner","year":"1995","unstructured":"Gardner MJ, Jones LM, Catterall JB, Turner GA . Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis. Cancer Lett 1995; 91: 229\u2013234.","journal-title":"Cancer Lett"},{"key":"BFonc2016509_CR5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1148\/radiology.169.3.3186993","volume":"169","author":"JN Buy","year":"1988","unstructured":"Buy JN, Moss AA, Ghossain MA, Sciot C, Malbec L, Vadrot D et al. Peritoneal implants from ovarian tumors: CT findings. Radiology 1988; 169: 691\u2013694.","journal-title":"Radiology"},{"key":"BFonc2016509_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nrc1611","volume":"5","author":"H Naora","year":"2005","unstructured":"Naora H, Montell DJ . Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 2005; 5: 355\u2013366.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2016509_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/carcin\/bgr230","volume":"33","author":"J Cai","year":"2012","unstructured":"Cai J, Tang H, Xu L, Wang X, Yang C, Ruan S et al. Fibroblasts in omentum activated by tumor cells promote ovarian cancer growth, adhesion and invasiveness. Carcinogenesis 2012; 33: 20\u201329.","journal-title":"Carcinogenesis"},{"key":"BFonc2016509_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan D, Coussens LM . Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21: 309\u2013322.","journal-title":"Cancer Cell"},{"key":"BFonc2016509_CR9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrc865","volume":"2","author":"AF Chambers","year":"2002","unstructured":"Chambers AF, Groom AC, MacDonald IC . Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563\u2013572.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2016509_CR10","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1172\/JCI74778","volume":"124","author":"HA Kenny","year":"2014","unstructured":"Kenny HA, Chiang CY, White EA, Schryver EM, Habis M, Romero IL et al. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest 2014; 124: 4614\u20134628.","journal-title":"J Clin Invest"},{"key":"BFonc2016509_CR11","doi-asserted-by":"publisher","first-page":"9319","DOI":"10.1158\/0008-5472.CAN-10-1783","volume":"70","author":"I Rizvi","year":"2010","unstructured":"Rizvi I, Celli JP, Evans CL, Abu-Yousif AO, Muzikansky A, Pogue BW et al. Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer. Cancer Res 2010; 70: 9319\u20139328.","journal-title":"Cancer Res"},{"key":"BFonc2016509_CR12","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1074\/jbc.M704855200","volume":"283","author":"AR Radjabi","year":"2008","unstructured":"Radjabi AR, Sawada K, Jagadeeswaran S, Eichbichler A, Kenny HA, Montag A et al. Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface. J Biol Chem 2008; 283: 2822\u20132834.","journal-title":"J Biol Chem"},{"key":"BFonc2016509_CR13","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1002\/ijc.26031","volume":"128","author":"RR Langley","year":"2011","unstructured":"Langley RR, Fidler IJ . The seed and soil hypothesis revisited\u2013the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 2011; 128: 2527\u20132535.","journal-title":"Int J Cancer"},{"key":"BFonc2016509_CR14","first-page":"1523","volume":"11","author":"T Bauknecht","year":"1991","unstructured":"Bauknecht T, Kommoss F, Birmelin G, von Kleist S, Kohler M, Pfleiderer A . Expression analysis of EGF-R and TGFa in human ovarian carcinomas. Anticancer Res 1991; 11: 1523\u20131528.","journal-title":"Anticancer Res"},{"key":"BFonc2016509_CR15","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/0959-8049(92)90538-D","volume":"28\u2009A","author":"M Kohler","year":"1992","unstructured":"Kohler M, Bauknecht T, Grimm M, Birmelin G, Kommoss F, Wagner E . Epidermal growth factor receptor and transforming growth factor alpha expression in human ovarian carcinomas. European Journal of Cancer 1992; 28\u2009A: 1432\u20131437.","journal-title":"European Journal of Cancer"},{"key":"BFonc2016509_CR16","first-page":"941","volume":"21","author":"A D'Antonio","year":"2002","unstructured":"D'Antonio A, Losito S, Pignata S, Grassi M, Perrone F, De Luca A et al. Transforming growth factor alpha, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas. International Journal of Oncology 2002; 21: 941\u2013948.","journal-title":"International Journal of Oncology"},{"key":"BFonc2016509_CR17","first-page":"6166","volume":"48","author":"SP Langdon","year":"1988","unstructured":"Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, Hayward IP et al. Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res 1988; 48: 6166\u20136172.","journal-title":"Cancer Res"},{"key":"BFonc2016509_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1042\/BC20100117","volume":"103","author":"E Alt","year":"2011","unstructured":"Alt E, Yan Y, Gehmert S, Song YH, Altman A, Gehmert S et al. Fibroblasts share mesenchymal phenotypes with stem cells, but lack their differentiation and colony-forming potential. Biol Cell 2011; 103: 197\u2013208.","journal-title":"Biol Cell"},{"key":"BFonc2016509_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev.immunol.18.1.621","volume":"18","author":"M Karin","year":"2000","unstructured":"Karin M, Ben-Neriah Y . Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annual Review of Immunology 2000; 18: 621\u2013663.","journal-title":"Annual Review of Immunology"},{"issue":"2","key":"BFonc2016509_CR20","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1007\/s12035-016-9705-9","volume":"54","author":"Pratap Karki","year":"2016","unstructured":"Karki P, Johnson Jr J, Son DS, Aschner M, Lee E . Transcriptional Regulation of Human Transforming Growth Factor-alpha in Astrocytes. Molecular neurobiology 2016, e-pub ahead of print 21 January 2016 doi:10.1007\/s12035-016-9705-9.","journal-title":"Molecular Neurobiology"},{"key":"BFonc2016509_CR21","doi-asserted-by":"crossref","first-page":"30765","DOI":"10.1016\/S0021-9258(18)47345-0","volume":"269","author":"EE Qwarnstrom","year":"1994","unstructured":"Qwarnstrom EE, Ostberg CO, Turk GL, Richardson CA, Bomsztyk K . Fibronectin attachment activates the NF-kappa B p50\/p65 heterodimer in fibroblasts and smooth muscle cells. J Biol Chem 1994; 269: 30765\u201330768.","journal-title":"J Biol Chem"},{"key":"BFonc2016509_CR22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1158\/1535-7163.MCT-05-0303","volume":"5","author":"PW Szlosarek","year":"2006","unstructured":"Szlosarek PW, Grimshaw MJ, Kulbe H, Wilson JL, Wilbanks GD, Burke F et al. Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. Molecular Cancer Therapeutics 2006; 5: 382\u2013390.","journal-title":"Molecular Cancer Therapeutics"},{"key":"BFonc2016509_CR23","doi-asserted-by":"publisher","first-page":"12645","DOI":"10.1038\/ncomms12645","volume":"7","author":"F Coscia","year":"2016","unstructured":"Coscia F, Watters KM, Curtis M, Eckert MA, Chiang CY, Tyanova S et al. Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nat Commun 2016; 7: 12645.","journal-title":"Nat Commun"},{"key":"BFonc2016509_CR24","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1158\/0008-5472.CAN-13-3198","volume":"74","author":"C Wang","year":"2014","unstructured":"Wang C, Cicek MS, Charbonneau B, Kalli KR, Armasu SM, Larson MC et al. Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian cancer. Cancer Res 2014; 74: 3084\u20133091.","journal-title":"Cancer Res"},{"key":"BFonc2016509_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrg2540","volume":"10","author":"H Cedar","year":"2009","unstructured":"Cedar H, Bergman Y, Linking DNA . methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009; 10: 295\u2013304.","journal-title":"Nat Rev Genet"},{"key":"BFonc2016509_CR26","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.cell.2007.05.009","volume":"129","author":"A Barski","year":"2007","unstructured":"Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z et al. High-resolution profiling of histone methylations in the human genome. Cell 2007; 129: 823\u2013837.","journal-title":"Cell"},{"key":"BFonc2016509_CR27","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ccr.2007.10.014","volume":"12","author":"JC Lin","year":"2007","unstructured":"Lin JC, Jeong S, Liang G, Takai D, Fatemi M, Tsai YC et al. Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer cell 2007; 12: 432\u2013444.","journal-title":"Cancer cell"},{"key":"BFonc2016509_CR28","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1101\/gr.143008.112","volume":"22","author":"TK Kelly","year":"2012","unstructured":"Kelly TK, Liu Y, Lay FD, Liang G, Berman BP, Jones PA . Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules. Genome Res 2012; 22: 2497\u20132506.","journal-title":"Genome Res"},{"key":"BFonc2016509_CR29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.gene.2005.10.018","volume":"366","author":"N Normanno","year":"2006","unstructured":"Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366: 2\u201316.","journal-title":"Gene"},{"key":"BFonc2016509_CR30","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00109-006-0054-4","volume":"84","author":"H Lassus","year":"2006","unstructured":"Lassus H, Sihto H, Leminen A, Joensuu H, Isola J, Nupponen NN et al. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. Journal of Molecular Medicine 2006; 84: 671\u2013681.","journal-title":"Journal of Molecular Medicine"},{"key":"BFonc2016509_CR31","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/PGP.0b013e31815d060d","volume":"27","author":"H Brustmann","year":"2008","unstructured":"Brustmann H . Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome. Int J Gynecol Pathol 2008; 27: 380\u2013389.","journal-title":"Int J Gynecol Pathol"},{"key":"BFonc2016509_CR32","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrc3309","volume":"12","author":"Y Yarden","year":"2012","unstructured":"Yarden Y, Pines G . The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 2012; 12: 553\u2013563.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2016509_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","volume":"79","author":"R Roskoski Jr","year":"2014","unstructured":"Roskoski R Jr . The ErbB\/HER family of protein-tyrosine kinases and cancer. Pharmacological Research 2014; 79: 34\u201374.","journal-title":"Pharmacological Research"},{"key":"BFonc2016509_CR34","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/ijc.23109","volume":"122","author":"P Andersen","year":"2008","unstructured":"Andersen P, Pedersen MW, Woetmann A, Villingshoj M, Stockhausen MT, Odum N et al. EGFR induces expression of IRF-1 via STAT1 and STAT3 activation leading to growth arrest of human cancer cells. Int J Cancer 2008; 122: 342\u2013349.","journal-title":"Int J Cancer"},{"key":"BFonc2016509_CR35","doi-asserted-by":"publisher","first-page":"6040","DOI":"10.1038\/onc.2015.52","volume":"34","author":"C He","year":"2015","unstructured":"He C, Lv X, Hua G, Lele SM, Remmenga S, Dong J et al. YAP forms autocrine loops with the ERBB pathway to regulate ovarian cancer initiation and progression. Oncogene 2015; 34: 6040\u20136054.","journal-title":"Oncogene"},{"key":"BFonc2016509_CR36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S1359-6101(01)00020-X","volume":"13","author":"F Balkwill","year":"2002","unstructured":"Balkwill F . Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 2002; 13: 135\u2013141.","journal-title":"Cytokine Growth Factor Rev"},{"key":"BFonc2016509_CR37","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1593\/neo.09112","volume":"11","author":"J Kwong","year":"2009","unstructured":"Kwong J, Chan FL, Wong KK, Birrer MJ, Archibald KM, Balkwill FR et al. Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. Neoplasia 2009; 11: 529\u2013541.","journal-title":"Neoplasia"},{"key":"BFonc2016509_CR38","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1172\/JCI116446","volume":"91","author":"MS Naylor","year":"1993","unstructured":"Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR . Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 1993; 91: 2194\u20132206.","journal-title":"J Clin Invest"},{"key":"BFonc2016509_CR39","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/00004347-199701000-00010","volume":"16","author":"H Niikura","year":"1997","unstructured":"Niikura H, Sasano H, Sato S, Yajima A . Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Int J Gynecol Pathol 1997; 16: 60\u201368.","journal-title":"Int J Gynecol Pathol"},{"key":"BFonc2016509_CR40","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.bbrc.2015.03.180","volume":"461","author":"X Qiu","year":"2015","unstructured":"Qiu X, Cheng JC, Klausen C, Fan Q, Chang HM, So WK et al. Transforming growth factor-alpha induces human ovarian cancer cell invasion by down-regulating E-cadherin in a Snail-independent manner. Biochemical and Biophysical Research Communications 2015; 461: 128\u2013135.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"BFonc2016509_CR41","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/modpathol.3800575","volume":"19","author":"S Stadlmann","year":"2006","unstructured":"Stadlmann S, Gueth U, Reiser U, Diener PA, Zeimet AG, Wight E et al. Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Mod Pathol 2006; 19: 607\u2013610.","journal-title":"Mod Pathol"},{"key":"BFonc2016509_CR42","doi-asserted-by":"publisher","first-page":"8637","DOI":"10.1158\/1078-0432.CCR-05-1436","volume":"11","author":"A Psyrri","year":"2005","unstructured":"Psyrri A, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S et al. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res 2005; 11: 8637\u20138643.","journal-title":"Clin Cancer Res"},{"key":"BFonc2016509_CR43","doi-asserted-by":"publisher","first-page":"408","DOI":"10.4161\/cbt.19292","volume":"13","author":"T Ohta","year":"2012","unstructured":"Ohta T, Ohmichi M, Shibuya T, Takahashi T, Tsutsumi S, Takahashi K et al. Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells. Cancer biology and Therapy 2012; 13: 408\u2013416.","journal-title":"Cancer biology and Therapy"},{"key":"BFonc2016509_CR44","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1158\/0008-5472.CAN-14-1801","volume":"75","author":"CS Milagre","year":"2015","unstructured":"Milagre CS, Gopinathan G, Everitt G, Thompson RG, Kulbe H, Zhong H et al. Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer. Cancer Res 2015; 75: 1255\u20131264.","journal-title":"Cancer Res"},{"key":"BFonc2016509_CR45","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12943-015-0366-5","volume":"14","author":"W Wen","year":"2015","unstructured":"Wen W, Wu J, Liu L, Tian Y, Buettner R, Hsieh MY et al. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK\/STAT3 pathways in human ovarian cancer. Molecular Cancer 2015; 14: 100.","journal-title":"Molecular Cancer"},{"key":"BFonc2016509_CR46","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.canep.2012.06.005","volume":"36","author":"T Gui","year":"2012","unstructured":"Gui T, Shen K . The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. Cancer Epidemiology 2012; 36: 490\u2013496.","journal-title":"Cancer Epidemiology"},{"key":"BFonc2016509_CR47","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1200\/JCO.2013.50.5669","volume":"32","author":"IB Vergote","year":"2014","unstructured":"Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. J Clin Oncol 2014; 32: 320\u2013326.","journal-title":"J Clin Oncol"},{"key":"BFonc2016509_CR48","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ygyno.2010.08.008","volume":"119","author":"SV Blank","year":"2010","unstructured":"Blank SV, Christos P, Curtin JP, Goldman N, Runowicz CD, Sparano JA et al. Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. Gynecol Oncol 2010; 119: 451\u2013456.","journal-title":"Gynecol Oncol"},{"key":"BFonc2016509_CR49","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1158\/1078-0432.CCR-07-4171","volume":"14","author":"KD Steffensen","year":"2008","unstructured":"Steffensen KD, Waldstrom M, Olsen DA, Corydon T, Lorentzen KA, Knudsen HJ et al. Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors. Clin Cancer Res 2008; 14: 3278\u20133282.","journal-title":"Clin Cancer Res"},{"key":"BFonc2016509_CR50","first-page":"107","volume":"4","author":"E Teplinsky","year":"2015","unstructured":"Teplinsky E, Muggia F . EGFR and HER2: is there a role in ovarian cancer? Transl Cancer Res 2015; 4: 107\u2013117.","journal-title":"Transl Cancer Res"},{"key":"BFonc2016509_CR51","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1002\/cncr.28864","volume":"120","author":"M Burotto","year":"2014","unstructured":"Burotto M, Chiou VL, Lee JM, Kohn EC . The MAPK pathway across different malignancies: a new perspective. Cancer 2014; 120: 3446\u20133456.","journal-title":"Cancer"},{"key":"BFonc2016509_CR52","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s00404-014-3377-3","volume":"290","author":"H Li","year":"2014","unstructured":"Li H, Zeng J, Shen K . PI3K\/AKT\/mTOR signaling pathway as a therapeutic target for ovarian cancer. Archives of Gynecology and Obstetrics 2014; 290: 1067\u20131078.","journal-title":"Archives of Gynecology and Obstetrics"},{"key":"BFonc2016509_CR53","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1038\/bjc.2013.529","volume":"109","author":"S Glaysher","year":"2013","unstructured":"Glaysher S, Bolton LM, Johnson P, Atkey N, Dyson M, Torrance C et al. Targeting EGFR and PI3K pathways in ovarian cancer. Br J Cancer 2013; 109: 1786\u20131794.","journal-title":"Br J Cancer"},{"key":"BFonc2016509_CR54","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/path.4258","volume":"232","author":"TS Lau","year":"2014","unstructured":"Lau TS, Chung TK, Cheung TH, Chan LK, Cheung LW, Yim SF et al. Cancer cell-derived lymphotoxin mediates reciprocal tumour-stromal interactions in human ovarian cancer by inducing CXCL11 in fibroblasts. J Pathol 2014; 232: 43\u201356.","journal-title":"J Pathol"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/onc2016509.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/onc2016509","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/onc.2016.509","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/onc2016509.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T05:00:58Z","timestamp":1684472458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2016509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,6]]},"references-count":54,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["BFonc2016509"],"URL":"https:\/\/doi.org\/10.1038\/onc.2016.509","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,6]]},"assertion":[{"value":"4 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}